阿斯利康重磅高血压药物达到临床主要终点

Core Insights - AstraZeneca's drug baxdrostat has achieved its primary goal in a late-stage clinical trial for treatment-resistant hypertension, significantly lowering blood pressure [1] - The company plans to submit baxdrostat for approval by the end of the year and anticipates annual sales could exceed $5 billion [1] - Additional indications for baxdrostat under clinical research include chronic kidney disease and heart failure prevention [1]